lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...3031323334353637383940...4546»
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Management of corona virus disease-19 (COVID-19): the Zhejiang experience (Pubmed Central) -  Mar 17, 2020   
    Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviraleffects in COVID-19...Therefore, two weeks' quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience above and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.
  • ||||||||||  lamivudine / Generic mfg., abacavir/lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Small Airway Disease and Brochodialator Response in Children with HIV in Sub Saharan Africa (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area F) -  Mar 15, 2020 - Abstract #ATS2020ATS_9845;    
    The study participants were on a combination of either Abacavir, Lamivudine, Lopinavir Ritonavir, Zidovudine or Nevirapine. The mean z scores for all acceptable spirometry were: %FEV/FVC 82%; FEV: pre BDR zFEV1 -2.27, postBDR zFEV1 -2.03; % change postBDR 4.28%; least changes in FVC: pre BDR zFVC -1,92 post BDR zFVC -1,88; % change post BDR 0.62%; with significant changes in FEF 25-75: pre BDR zFEF 25-75 -1.63; post BDR zFEF 25-75 -1,14; % change post BDR 21.07%CONCLUSIONS.Spirometric values of FEF 25-75 BDR is useful to diagnose SAD in children and helps identify children that require long term follow-up of their lung function.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  The 2019 Novel Coronavirus Outbreak - A Global Threat. (Pubmed Central) -  Mar 11, 2020   
    Isolation of symptomatic cases and home quarantine of asymptomatic contacts is recommended. To conclude, controlling this highly transmissible disease requires international co-ordination.
  • ||||||||||  New P3 trial:  THDMS-COVID19: Fight COVID-19 Trial (clinicaltrials.gov) -  Mar 11, 2020   
    P3,  N=80, Not yet recruiting,